Medtronic and Methinks AI Collaborate to Revolutionize Early Stroke Detection and Treatment
Portage, Michigan – April 2, 2025 – Medtronic plc, a global leader in medical technology, announced today a strategic collaboration with Methinks AI, a Barcelona-based company specializing in artificial intelligence software for stroke detection. This partnership aims to integrate Methinks’ AI-powered applications with Medtronic’s stroke treatment devices to improve patient outcomes across Central and Eastern Europe, Africa, Turkey, and the Middle East.
Methinks AI’s Technology Enhances Medtronic’s Stroke Care Portfolio
Methinks’ AI software analyzes standard CT scans to identify critical conditions such as large vessel occlusions and intracranial hemorrhages. By delivering real-time alerts via cloud-based platforms and collaboration tools, the technology empowers healthcare providers to act quickly—even in facilities lacking advanced imaging systems.
Medtronic’s Advanced Stroke Devices Combined with Methinks AI Streamline Patient Care
The integration of Methinks’ software with Medtronic’s hardware portfolio, including clot aspiration and stent retriever devices, is designed to accelerate triage and treatment. This partnership addresses challenges faced by healthcare professionals by improving care coordination and reducing treatment delays.
Leaders Maria Zvereva and Pau Rodríguez Highlight Shared Vision for Improving Stroke Outcomes
Maria Zvereva, Medtronic’s neurovascular marketing leader for the CEMA region, emphasized the importance of this collaboration in providing innovative tools to healthcare teams. Pau Rodríguez, CEO of Methinks AI, expressed enthusiasm about expanding access to their AI-powered stroke detection solutions.
Medtronic continues to build on its investments in AI-enhanced healthcare solutions, furthering its mission to improve patient lives through advanced technology.
Financial details of the partnership have not been disclosed.
By
